BAR1 LIFE Stock Australian S.E.

BD1

Pharmaceuticals

End-of-day quote Australian S.E. Other stock markets			5-day change	1st Jan Change
- ^AUD	-.--%		-.--%	-

06-25	Inoviq Says CAR-Exosome Platform Showed In Vitro Tumor-Killing Activity in Ovarian Cancer; Shares Down 4%	MT
02-18	INOVIQ Ltd Reports Earnings Results for the Half Year Ended December 31, 2025	CI

INOVIQ Ltd is an Australia-based biotechnology company developing diagnostics and therapeutics for cancer. The Company's commercialized products include EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The Company is also advancing clinical-stage diagnostics for the detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumors.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.1950AUD

Average target price

0.7000AUD

Spread / Average Target

+258.97%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	30.27M 21.18M 18.56M 17.23M 15.83M 29.83M 2.04B 205M 80.32M 1B 79.5M 77.78M 3.45B	P/E 2026 *	-5.38x	P/E 2027 *	-5.38x
Enterprise Value	30.27M 21.18M 18.56M 17.23M 15.83M 29.83M 2.04B 205M 80.32M 1B 79.5M 77.78M 3.45B	EV / Sales 2026 *	33.6x	EV / Sales 2027 *	21.6x
Free-Float	66.05%	Yield 2026 *	-	Yield 2027 *	-

06-25	Inoviq Says CAR-Exosome Platform Showed In Vitro Tumor-Killing Activity in Ovarian Cancer; Shares Down 4%	MT
02-18	INOVIQ Ltd Reports Earnings Results for the Half Year Ended December 31, 2025	CI
12-23	INOVIQ Appoints Chief Scientific Officer	MT
12-23	INOVIQ Limited Announces Management Changes, Effective January 12, 2026	CI
12-18	Inoviq says Peter Gunzburg elected to role of chairman	RE
11-27	Inoviq Ltd Elects Peter Gunzburg as Non-Executive Director	CI
11-27	Inoviq says chairman David Williams to step down at year-end	RE
17/10/25	INOVIQ Ltd Announces Appointment of Peter Gunzburg as A Non-Executive Director, Effective 20 October 2025	CI
13/10/25	Inoviq completes A$9.5 million placement	RE
09/10/25	Inoviq Ltd seeks trading halt	RE
26/09/25	INOVIQ Secures Worldwide License for Development, Commercialization of Ovarian Cancer Detection Biomarkers; Shares Jump 5%	MT
26/09/25	Inoviq licences worldwide rights to ovarian cancer biomarker IP from UniQuest	RE
22/08/25	INOVIQ Ltd Reports Earnings Results for the Full Year Ended June 30, 2025	CI

07/07/23	INOVIQ AND PROMEGA ANNOUNCE GLOBAL JOINT MARKETING AGREEMENT FOR EXO-NET EXOSOME ISOLATION AND NUCLEIC ACID PURIFICATION SOLUTIONS	AQ
27/07/22	INOVIQ : IIQ Appendix 4C & Quarterly Activities Report - June 2022	PU
29/04/22	INOVIQ : IIQ Appendix 4C & Quarterly Activities Report - March 2022	PU
06/04/22	INOVIQ : Updated Investor Presentation	PU
07/12/21	BARD1 Life Sciences : Application for quotation of securities - BD1	PU

Manager	Title	Age	Since
Leearne Hinch CEO	Chief Executive Officer	-	07/11/2016
Mark Edwards DFI	Director of Finance/CFO	-	02/11/2022
Rebecca Lim CTO	Chief Tech/Sci/R&D Officer	-	12/01/2026

Director	Title	Age	Since
Peter Gunzburg CHM	Chairman	74	-
Philip Powell BRD	Director/Board Member	67	18/06/2019
Geoff Cumming CHM	Chairman	-	28/07/2020

BAR1 LIFE Stock Australian S.E.

Stocks

BD1

Pharmaceuticals

Valuation: BAR1 LIFE

Latest news : BAR1 LIFE

Press Releases: BAR1 LIFE

Managers and Directors: BAR1 LIFE

Other Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BAR1 LIFE	-.--%	-.--%	-	-	19.21M
ELI LILLY AND COMPANY	+1.87%	+1.27%	+48.21%	+157.79%	1,037B
JOHNSON & JOHNSON	+1.57%	+3.57%	+53.10%	+51.33%	615B
ABBVIE INC.	+1.75%	+1.30%	+35.24%	+79.98%	448B
ROCHE HOLDING AG	+5.70%	+6.00%	+34.52%	+28.52%	326B
NOVARTIS AG	+1.05%	+3.46%	+36.94%	+40.44%	293B
ASTRAZENECA PLC	-0.28%	+0.54%	+18.94%	+17.77%	264B
NOVO NORDISK A/S	+0.25%	-4.62%	-27.66%	-41.76%	216B
AMGEN INC.	+0.55%	-0.72%	+19.30%	+56.69%	198B
GILEAD SCIENCES, INC.	-0.15%	-4.37%	+14.78%	+67.84%	162B
Average	+1.22%	+1.12%	+25.93%	+50.96%	395.27B
Weighted average by Cap.	+1.64%	+1.47%	+35.35%	+75.90%

	2026 *	2027 *
Net sales	900K 630K 552K 512K 471K 887K 60.77M 6.1M 2.39M 29.73M 2.36M 2.31M 103M	1.4M 980K 858K 797K 732K 1.38M 94.52M 9.49M 3.72M 46.25M 3.68M 3.6M 160M
Net income	-	-
Net Debt	-	-